Compare NABL & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NABL | ARVN |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 649.8M | 600.2M |
| IPO Year | 2021 | 2018 |
| Metric | NABL | ARVN |
|---|---|---|
| Price | $3.86 | $8.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 19 |
| Target Price | $8.31 | ★ $15.05 |
| AVG Volume (30 Days) | ★ 2.5M | 547.9K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | ★ $511,430,000.00 | $262,600,000.00 |
| Revenue This Year | $11.04 | N/A |
| Revenue Next Year | $8.53 | N/A |
| P/E Ratio | ★ N/A | $5.15 |
| Revenue Growth | ★ 9.71 | N/A |
| 52 Week Low | $2.92 | $6.97 |
| 52 Week High | $8.74 | $14.22 |
| Indicator | NABL | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 48.26 | 43.94 |
| Support Level | $3.81 | $8.37 |
| Resistance Level | $4.39 | $8.90 |
| Average True Range (ATR) | 0.23 | 0.32 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 45.06 | 17.32 |
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.